Impact of Matrix Metalloproteinase 9 on COPD Development in Polish Patients: Genetic Polymorphism, Protein Level, and Their Relationship with Lung Function

Table 3

MMP-9, MMP-9/TIMP1, and MMP-9/TIMP2 proteins level in serum of COPD patient and healthy control groups.

Proteins levels	Groups				p value
	COPD patients; N=60	CTR; N=61	CTR smokers; N=23	CTR non-smokers; N=38	p1	p2	p3	p4
MMP-9 [ng/ml]	149.0 ± 72.3	26.5 ± 6.5	27.5 ± 7.9	25.9 ± 5.6	<0.00001	<0.00001	<0.00001	0.37
MMP-9/TIMP1 [pg/ml]	3146.8 ± 491.9	2970.1 ± 485.1	3135.8 ± 180.4	2869.8 ± 578.8	0.04	0.9	0.10	0.03
MMP-9/TIMP2 [ng/ml]	6.1 ± 4.7	6.1 ± 2.0	5.8 ± 1.4	6.3 ± 2.3	0.9	0.6	0.82	0.31

N, number of individuals; COPD, chronic obstructive pulmonary disease groups; CTR, control group; , COPD patients versus CTR; , COPD patients versus CTR smokers; , COPD patients versus CTR nonsmokers; , CTR smokers versus CTR nonsmokers.